Fluoro-2-deoxy-D-glucose (FDG)-PET in APOEε4 carriers in the Australian population

M. Rimajova, N.P. Lenzo, J.S. Wu, K.A. Bates, A. Campbell, S.S. Dhaliwal, M. Mccarthy, M.A. Rodrigues, Athena Paton, C. Rowe, Jonathan Foster, Ralph Martins

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Apolipoprotein E-epsilon 4 (APOE epsilon 4) has been associated with increased risk of developing Alzheimer's disease (AD) and regional cerebral glucose hypometabolism, as measured by fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). We report here preliminary data from studies that aim to determine whether cerebral glucose hypometabolism is observed in APOE epsilon 4 positive, cognitively intact individuals between the ages of 50 and 80, and whether there is an additional impact of subjective memory complainer (SMC) status on glucose metabolism determined by NeuroStat analysis. FDG-PET was conducted in 30 community dwelling, APOE-epsilon 4 carriers without clinical evidence of dementia and objective cognitive impairment as assessed using a neuropsychological battery. Neurological soft-signs (NSS) were also assessed. Glucose hypometabolism was demonstrated in the anterior and posterior cingulate cortex and in the temporal association cortices in APOE epsilon 4 carriers compared to the normative NeuroStat database. This pattern was particularly evident in APOE epsilon 4 heterozygous individuals. SMC showed hypometabolism in the aforementioned brain regions, whereas non-SMC showed no significant pattern of glucose hypometabolism. FDG-PET with NeuroStat analysis showed that APOE epsilon 4 carriers have mild glucose hypometabolism in areas associated with AD. SMC may be associated with AD-related differences in regional cerebral glucose metabolism. These findings are currently being investigated in a larger group of APOE epsilon 4 carriers.
Original languageEnglish
Pages (from-to)137-146
JournalJournal of Alzheimer's Disease
Volume13
Publication statusPublished - 2008

Fingerprint Dive into the research topics of 'Fluoro-2-deoxy-D-glucose (FDG)-PET in APOEε4 carriers in the Australian population'. Together they form a unique fingerprint.

Cite this